Cargando…

The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib

Background: Chorea-acanthocytosis (ChAc) is a rare hereditary neurodegenerative disease with deformed red blood cells (RBCs), so-called acanthocytes, as a typical marker of the disease. Erythrocyte sedimentation rate (ESR) was recently proposed as a diagnostic biomarker. To date, there is no treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabe, Antonia, Kihm, Alexander, Darras, Alexis, Peikert, Kevin, Simionato, Greta, Dasanna, Anil Kumar, Glaß, Hannes, Geisel, Jürgen, Quint, Stephan, Danek, Adrian, Wagner, Christian, Fedosov, Dmitry A., Hermann, Andreas, Kaestner, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151862/
https://www.ncbi.nlm.nih.gov/pubmed/34066168
http://dx.doi.org/10.3390/biom11050727
_version_ 1783698483475120128
author Rabe, Antonia
Kihm, Alexander
Darras, Alexis
Peikert, Kevin
Simionato, Greta
Dasanna, Anil Kumar
Glaß, Hannes
Geisel, Jürgen
Quint, Stephan
Danek, Adrian
Wagner, Christian
Fedosov, Dmitry A.
Hermann, Andreas
Kaestner, Lars
author_facet Rabe, Antonia
Kihm, Alexander
Darras, Alexis
Peikert, Kevin
Simionato, Greta
Dasanna, Anil Kumar
Glaß, Hannes
Geisel, Jürgen
Quint, Stephan
Danek, Adrian
Wagner, Christian
Fedosov, Dmitry A.
Hermann, Andreas
Kaestner, Lars
author_sort Rabe, Antonia
collection PubMed
description Background: Chorea-acanthocytosis (ChAc) is a rare hereditary neurodegenerative disease with deformed red blood cells (RBCs), so-called acanthocytes, as a typical marker of the disease. Erythrocyte sedimentation rate (ESR) was recently proposed as a diagnostic biomarker. To date, there is no treatment option for affected patients, but promising therapy candidates, such as dasatinib, a Lyn-kinase inhibitor, have been identified. Methods: RBCs of two ChAc patients during and after dasatinib treatment were characterized by the ESR, clinical hematology parameters and the 3D shape classification in stasis based on an artificial neural network. Furthermore, mathematical modeling was performed to understand the contribution of cell morphology and cell rigidity to the ESR. Microfluidic measurements were used to compare the RBC rigidity between ChAc patients and healthy controls. Results: The mechano-morphological characterization of RBCs from two ChAc patients in an off-label treatment with dasatinib revealed differences in the ESR and the acanthocyte count during and after the treatment period, which could not directly be related to each other. Clinical hematology parameters were in the normal range. Mathematical modeling indicated that RBC rigidity is more important for delayed ESR than cell shape. Microfluidic experiments confirmed a higher rigidity in the normocytes of ChAc patients compared to healthy controls. Conclusions: The results increase our understanding of the role of acanthocytes and their associated properties in the ESR, but the data are too sparse to answer the question of whether the ESR is a suitable biomarker for treatment success, whereas a correlation between hematological and neuronal phenotype is still subject to verification.
format Online
Article
Text
id pubmed-8151862
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81518622021-05-27 The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib Rabe, Antonia Kihm, Alexander Darras, Alexis Peikert, Kevin Simionato, Greta Dasanna, Anil Kumar Glaß, Hannes Geisel, Jürgen Quint, Stephan Danek, Adrian Wagner, Christian Fedosov, Dmitry A. Hermann, Andreas Kaestner, Lars Biomolecules Article Background: Chorea-acanthocytosis (ChAc) is a rare hereditary neurodegenerative disease with deformed red blood cells (RBCs), so-called acanthocytes, as a typical marker of the disease. Erythrocyte sedimentation rate (ESR) was recently proposed as a diagnostic biomarker. To date, there is no treatment option for affected patients, but promising therapy candidates, such as dasatinib, a Lyn-kinase inhibitor, have been identified. Methods: RBCs of two ChAc patients during and after dasatinib treatment were characterized by the ESR, clinical hematology parameters and the 3D shape classification in stasis based on an artificial neural network. Furthermore, mathematical modeling was performed to understand the contribution of cell morphology and cell rigidity to the ESR. Microfluidic measurements were used to compare the RBC rigidity between ChAc patients and healthy controls. Results: The mechano-morphological characterization of RBCs from two ChAc patients in an off-label treatment with dasatinib revealed differences in the ESR and the acanthocyte count during and after the treatment period, which could not directly be related to each other. Clinical hematology parameters were in the normal range. Mathematical modeling indicated that RBC rigidity is more important for delayed ESR than cell shape. Microfluidic experiments confirmed a higher rigidity in the normocytes of ChAc patients compared to healthy controls. Conclusions: The results increase our understanding of the role of acanthocytes and their associated properties in the ESR, but the data are too sparse to answer the question of whether the ESR is a suitable biomarker for treatment success, whereas a correlation between hematological and neuronal phenotype is still subject to verification. MDPI 2021-05-12 /pmc/articles/PMC8151862/ /pubmed/34066168 http://dx.doi.org/10.3390/biom11050727 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rabe, Antonia
Kihm, Alexander
Darras, Alexis
Peikert, Kevin
Simionato, Greta
Dasanna, Anil Kumar
Glaß, Hannes
Geisel, Jürgen
Quint, Stephan
Danek, Adrian
Wagner, Christian
Fedosov, Dmitry A.
Hermann, Andreas
Kaestner, Lars
The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib
title The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib
title_full The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib
title_fullStr The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib
title_full_unstemmed The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib
title_short The Erythrocyte Sedimentation Rate and Its Relation to Cell Shape and Rigidity of Red Blood Cells from Chorea-Acanthocytosis Patients in an Off-Label Treatment with Dasatinib
title_sort erythrocyte sedimentation rate and its relation to cell shape and rigidity of red blood cells from chorea-acanthocytosis patients in an off-label treatment with dasatinib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151862/
https://www.ncbi.nlm.nih.gov/pubmed/34066168
http://dx.doi.org/10.3390/biom11050727
work_keys_str_mv AT rabeantonia theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT kihmalexander theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT darrasalexis theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT peikertkevin theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT simionatogreta theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT dasannaanilkumar theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT glaßhannes theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT geiseljurgen theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT quintstephan theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT danekadrian theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT wagnerchristian theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT fedosovdmitrya theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT hermannandreas theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT kaestnerlars theerythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT rabeantonia erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT kihmalexander erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT darrasalexis erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT peikertkevin erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT simionatogreta erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT dasannaanilkumar erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT glaßhannes erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT geiseljurgen erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT quintstephan erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT danekadrian erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT wagnerchristian erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT fedosovdmitrya erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT hermannandreas erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib
AT kaestnerlars erythrocytesedimentationrateanditsrelationtocellshapeandrigidityofredbloodcellsfromchoreaacanthocytosispatientsinanofflabeltreatmentwithdasatinib